Atea Pharmaceuticals (NASDAQ:AVIR) Target Lowered by SVB Leerink LLC to $20.00

StockMarketDaily.co reports: stock has undergone multiple analysts rating changes in the recent past.  stock Target Lowered by   SVB Leerink LLC on 10/20/2021. In a note to investors, the firm issued a new target price of $20.00. The analysts previously had $60.00 target price.

View More Atea Pharmaceuticals (NASDAQ:AVIR) Target Lowered by SVB Leerink LLC to $20.00

Atea Pharmaceuticals (NASDAQ:AVIR) Target Raised by JPMorgan Chase & Co. to $61.00

StockMarketDaily.co reports: Atea Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Atea Pharmaceuticals stock Target Raised by   JPMorgan Chase & Co. on 10/18/2021. In a note to investors, the firm issued a new target price of $61.00. The analysts previously had $56.00 target price.

View More Atea Pharmaceuticals (NASDAQ:AVIR) Target Raised by JPMorgan Chase & Co. to $61.00